News @Gotham

October 10, 2018 - Gotham Therapeutics Launches with $54 Million Series A

Gotham Therapeutics, a biotechnology company developing a novel drug class targeting RNA-modifying proteins, debuted today with a $54 million Series A financing co-led by founding investor Versant Ventures, Forbion and S.R. One. The syndicate also included Celgene Corporation and Alexandria Venture Investments.

 
nyc-muc-2-blurred.jpg

UPCOMING EVENT

BioEurope 2018

Meet the team at the 24th Annual International Partnering Conference BioEurope 2018, at the Bella Center in Copenhagen, Denmark, November 5-7, 2018.

Screen Shot 2018-09-21 at 9.06.18 AM.png
iStock-866419242.jpg

UPCOMING EVENT

J.P Morgan Week 2019

Meet the team at during J.P Morgan Week in San Francisco, CA, January 7–9, 2019.

Stay In Touch! 

Gotham Therapeutics will be at the forefront of epitranscriptomics research and drug discovery. Staying in touch with us means staying up-to-date on the field.

contact.jpg